Mr. Chairman, my name is Tara O'Toole. I am a
physician and public health professional by training, the Director of the Johns
Hopkins Center for Civilian Biodefense Strategies, and a faculty member of the
Bloomberg School of Public Health. From 1993-97 I served as Assistant Secretary
of Energy for Environment Safety and Health, and prior to that was a senior
analyst at the Congressional Office of Technology Assessment. It is a privilege
to come before you today to discuss the implications of President Bush's
proposed bill to create a Department of Homeland Security. I shall confine my
remarks to those aspects of the bill which deal with bioterrorism preparedness
and biodefense activities.
I strongly support the formation of a federal
department of Homeland Security as outlined by the U.S. National Commission on
National Security in the 21st Century (the "Hart-Rudman report").
It makes great sense, as President Bush has advocated, to consolidate some of
the many departments and agencies that share similar functions pertaining to
border security, customs procedures, etc. in order to achieve greater
collaborative power, efficiency and accountability.
There are some potential advantages to be gained
from placing bioterrorism preparedness and biodefense research and development
activities in a new federal agency. The activities dealing with the biodefense
mission are profoundly important to the nation's security and deserve the
attention and support the new agency is likely to command in the coming years.
If biodefense activities do not reside in the Homeland Defense
Department, there is some peril that these crucial functions will be neglected.
It is also important that the operational public health and medical biodefense
functions are integrated with national security objectives and that biodefense
experts be full participants in national security policymaking and strategic
planning.
I do, however, have serious concerns about the
implications of moving bioterrorism preparedness programs and biodefense
activities into the new agency, at least in the form presently envisioned.
A bioterrorist attack would be unlike any other
type of terrorist assault. This would not be a "lights and sirens" event
with firefighters, police and emergency rescue teams rushing to the scene of
attack. We will know we have been attacked with a biological weapon when victims
become ill and report to doctors' offices and emergency rooms. The "first
responders" to bioterrorism will be physicians and public health professionals
from state and local health agencies. The center of action will be hospitals,
clinics and laboratories. Bioterrorism response activities - which will
involve actions needed to treat the sick and perhaps stem the spread of
contagious disease - are quite different from the emergency response to other
types of catastrophic terrorism or to natural disasters.
Allowing for the inevitable transition period of
confusion and adjustment, it is likely that the new agency will be more
successful in instilling work habits of cooperation and collaboration to the
extent that the agency's mission is coherent and tightly interconnected. It is
not clear to me how or whether simply combining highly diverse functions from
dozens of existing agencies under a single department results in better
coordination or operational accountability. The description of the new
department seems to envision an agency that is largely dedicated to security
functions - border protection and control, vulnerability assessments of
critical infrastructures, etc. The bioterrorism related programs and the
scientific research and development aspects of the proposed department seem
strikingly different from everything else the agency would handle.
President Bush exercised admirable leadership
this winter when he greatly increased funding for bioterrorism preparedness
programs in Centers for Disease Control and Prevention (CDC) and initiated a
significant investment in bioterrorism research and development to be
administered through the National Institutes of Health (NIH). The anthrax
attacks of 2001 revealed that considerable improvement is needed in the
nation's ability to respond to such attacks. In the past six months, notable
progress has been made by the DHHS Office of Public Health Preparedness (OPHP).
The OPHP has set sound goals for upgrading local medical and public health
response capabilities, and the "critical benchmarks" it has demanded state
health authorities achieve will provide clear indications of progress. We should
consider disassembling and transferring this successful effort to the new
department only after careful deliberation of what might be lost in the process.
A recent poll reports that most Americans would seek and trust the advice of CDC
during a public health emergency. It is unclear if such public confidence would
transfer to the new department.
Part of the rationale behind the formation of a
Homeland Security agency, as I understand it, is to combine similar functions
- such as border control, customs services and immigration policy, etc.
- within a single department, thereby enhancing program focus, fostering
cooperation and collaboration and improving operational effectiveness. Yet
moving bioterrorism programs from the Department of Health and Human Services (DHHS)
to the proposed new agency will likely impede all these goals. Instead of
consolidating similar programs, the proposed agency would split bioterrorism
preparedness programs from the related but more encompassing mission of public
health protection which is DHHS' main objective.
Rather than producing organizational coherence
the proposed move would require that parallel capacities be created in both DHHS
and the new agency. Homeland Security could not hope to lead the development of
an effective bioterrorism response capability unless it were staffed with health
officials and scientists having considerable expertise and experience in
infectious disease, epidemic control, laboratory diagnosis, etc. Again, the
country would be forced to create parallel workforces: one in Homeland Security
for bioterrorism preparedness and another in DHHS for "normal" public health
functions.
Moving bioterrorism programs to Homeland Security
would disturb the existing relationships between DHHS bioterrorism programs and
the state and local public health departments and health care facilities which
are the central core of bioterrorism response. This is an especially important
consideration right now, when the federal grants to state health departments are
just hitting the streets and programs to upgrade response capacities at the
city, county and state level are getting started. Changing the federal partner
for these path-breaking grants will almost inevitably slow progress in this
critical arena.
Moving bioterrorism preparedness and response
activities out of DHHS may also sacrifice opportunities to construct dual use
programs. Ideally, one would design bioterrorism response systems that also
serve routine organizational purposes. There is a real danger that by
sequestering bioterrorism programs in Homeland Security, they will be treated as
"emergency use only" functions or seen as such, reducing the efficiency of
preparedness efforts, and quite possibly compromise response effectiveness.
Bioterrorism is, arguably, the type of terrorism
with which the country is least familiar and for which the United States is
least well prepared. A bioterrorist attack could be calamitous, killing many
thousands of people in the initial assault. The consequences would be sustained
and the crisis could continue for weeks or months, especially if the weapon used
were a contagious disease. The economic and social disruption would be
significant - as was seen in the aftermath of the 2001 anthrax attacks when
only 22 people were infected with a disease treatable with antibiotics.
According to the Defense Science Board, we currently have countermeasures of
some effectiveness (vaccines, drugs) for only 13 of the 50 pathogens most likely
to be used as bioweapons. In addition, the institutions and infrastructures
which would be at the core of bioterrorism response - health care
organizations and the public health system - are financially frail, highly
stressed, and have almost no capacity to contend with a sudden surge in demand
for care.
These factors make it imperative that we make
significant headway quickly in our capacity to manage bioterrorist threats. If
one looks at the description of the proposed department, bioterrorism-related
activities appear to be a tiny island of bioscience, medical and public health
functions within a gigantic ocean of security and border control operations. I
am skeptical that such an odd coupling can be made to work, particularly in the
short term when there is such need for rapid progress.
I am especially worried about the fate of science
and technology within the proposed department. Although there is clearly value
in linking national security needs to research and development priorities, it is
a very tall order to ask a single agency to develop national security strategy
and implement operations on the scale envisioned for Homeland Security AND
create a sophisticated scientific research and development capability over a
broad range of disciplines and technologies.
Furthermore, we should have no illusions that
creating a viable biodefense R&D capability is merely a matter of
transferring or consolidating existing capabilities and programs. Regardless of
how biodefense R&D programs are structured, the US government will have to
build its capacity in these areas far beyond our present state. This nation has
tremendous talent in bioscience and biotechnology - but the majority of talent
lives in universities and the private sector, not in government. Any successful
biodefense strategy must find ways to engage top scientists and young scientists
in these sectors. Creating a robust biodefense R&D capability should be a
top national security priority however we eventually design the architecture of
biosecurity functions.
Bioterrorism must be considered a special
category of terrorist threat. The potential power of bioweapons is easy to lose
sight of in the aftermath of the thankfully limited anthrax attacks of 2001. But
it is important to keep in mind that bioterrorism occupies a special category of
terrorist threat that deserves careful scrutiny. The Hart-Rudman Commission
noted in its first volume of analysis that
".the most serious threat to our security
may consist of unannounced attacks on American cities by sub-national groups
using genetically engineered pathogens." [US Commission on National
Security/21st Century, Sept. 15, 1999]
As we design programs to prevent and respond to
bioterrorist attacks we must proceed carefully, especially so since these
weapons are largely unfamiliar to policy experts. However we decide to proceed
in organizing federal bioterrorism activities, the nation's ability to respond
to mass casualty situations and to effectively contain spread of contagious
disease remains a grave concern. We must use our prodigious talent in bioscience
to create the vaccines and therapies needed to respond to the bioweapons of
today and of the future. We cannot afford a pause or loss of momentum in
accomplishing these tasks.